Welcome to our dedicated page for Aspire Biopharma Holdings news (Ticker: ASBPW), a resource for investors and traders seeking the latest updates and insights on Aspire Biopharma Holdings stock.
Aspire Biopharma Holdings, Inc. (Nasdaq: ASBP) is a biopharmaceutical company focused on a patent-pending sublingual delivery platform for drugs, nutraceuticals and supplements. The Aspire Biopharma news feed on Stock Titan brings together company announcements that explain how this platform is being advanced through clinical, regulatory, commercial and capital markets milestones.
Readers can follow detailed updates on Aspire Biopharma’s lead sublingual aspirin program, which the company is developing for the emergency treatment of suspected acute myocardial infarction. News items include results from pilot clinical trials comparing the sublingual aspirin formulation with chewed tablets, reports on rapid platelet inhibition, and disclosures about interactions with the U.S. Food and Drug Administration, such as pre‑IND meetings and regulatory guidance the company has received.
The feed also covers Aspire Biopharma’s corporate and listing developments, including communications about Nasdaq listing status, extensions granted by a Nasdaq Listing Qualifications Panel, transfer of the company’s stock to The Nasdaq Capital Market, and actions such as a 1‑for‑40 reverse stock split intended to help meet minimum bid price requirements. Investors can review how these steps fit into the company’s efforts to maintain its exchange listing and manage its capital structure.
In addition, Aspire Biopharma news highlights commercial activity around BUZZ BOMB™, the company’s proprietary sublingual caffeine supplement. Announcements describe product launches, sampling campaigns at fitness events, new manufacturing relationships, e‑commerce initiatives through a dedicated subsidiary, and brand partnerships such as the appointment of an elite ultra‑runner as a global brand ambassador. Updates on scientific team expansion, patent filings for the sublingual platform, and partnering discussions at major pharmaceutical conferences are also featured.
By reviewing this news stream, users can see how Aspire Biopharma presents the progress of its sublingual technology, from clinical data and regulatory planning to supplement commercialization and financing transactions. The page can be revisited regularly to monitor new press releases and disclosures as they are issued by the company.
Aspire Biopharma (Nasdaq: ASBP) filed an omnibus patent application with the U.S. Patent and Trademark Office on October 6, 2025, seeking broad protection for its sublingual drug delivery platform.
The application targets multiple drug classes and aims to protect features that increase API bioavailability and speed of onset via rapid sublingual absorption, bypassing first-pass metabolism, reducing GI exposure and interactions, and improving ease of administration in emergency settings. Aspire says the omnibus filing complements patents already filed and expands its intellectual property coverage across new product areas.
Aspire Biopharma (NASDAQ:ASBP) announced that Interim CEO Kraig Higginson will present and hold 1x1 investor meetings at the Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference on October 8-9, 2025.
The virtual presentation is scheduled for Wednesday, October 8 at 1:00 PM ET, with 1x1 meetings on October 8-9. Management will discuss pipeline progress and upcoming milestones, including a planned H2 2025 FDA meeting request and targeted NDA submission in H2 2025 for the lead sublingual high-dose aspirin program, and formulation completion and Phase 1 PK cross-over studies for sublingual semaglutide and a needle-free ED medication in H1–mid‑2026. For registration, investors are directed to the Noble conference site.
Aspire Biopharma (NASDAQ:ASBP) has outlined its milestone roadmap through 2026, focusing on its patent-pending sublingual drug delivery technology. The company's lead program targets an H2 2025 FDA submission for sublingual high-dose aspirin, following positive clinical results showing faster absorption and better bioavailability compared to traditional tablets.
The pipeline includes two additional key programs scheduled for H1 2026: a rapid-acting sublingual ED medication and a sublingual version of semaglutide for diabetes and weight management. Both programs will undergo Phase 1 pharmacokinetic studies in 2026. The company's strategy focuses on reformulating approved drugs for multi-billion-dollar markets, with plans to expand into CNS, men's health, and anti-nausea medications.
Aspire Biopharma (NASDAQ:ASBP) has launched an influencer marketing campaign for its BUZZ BOMB™ sublingual caffeine pre-workout product. The company has partnered with three prominent fitness influencers: Bobby Maximus (UFC fighter and fitness trainer), Brandon "MidWest Kong" Copeland (Brazilian Jiu-jitsu Black Belt), and Mustafa "The Stallion" Khater (professional bodybuilder), who collectively reach nearly 1 million followers.
BUZZ BOMB™ delivers 50mg of caffeine in less than two minutes through sublingual packets, available in four flavors. The product differentiates itself with rapid onset, convenient single-use packets, and precise energy management capabilities. The company reports positive initial launch feedback from fitness professionals and consumers at recent conventions.
Aspire Biopharma (NASDAQ:ASBP) has announced a strategic manufacturing partnership with SupraNaturals for its BUZZ BOMB™ pre-workout supplement. The company has placed an initial production order of 2 million servings (100,000 20-packs) of the supplement.
BUZZ BOMB™ contains 50mg of caffeine per serving in convenient stick packs that require no water mixing. The partnership with SupraNaturals, a cGMP-certified manufacturer, enables Aspire to scale production without capital expenditure while maintaining quality standards.
This strategic move positions Aspire to capture opportunities in the growing pre-workout supplement market, which is projected to expand from $19.6 billion in 2024 to $27.9 billion by 2030, representing a 5.9% CAGR.
Aspire Biopharma (NASDAQ:ASBP) has announced breakthrough final results from its clinical trial of a new sublingual aspirin product for treating suspected heart attacks. The study demonstrated that their formulation significantly inhibited serum thromboxane B2 (TxB2) within two minutes after dosing, acting approximately twice as fast as conventional chewed aspirin tablets.
The sublingual product, delivering 162.5 mg of aspirin, showed higher and more rapid mean plasma concentrations of acetylsalicylic acid compared to chewed tablets. This rapid inhibition is crucial during heart attacks, where blood clots can cause permanent muscle damage. With 18 million Americans living with coronary artery disease and 800,000 annual heart attacks, Aspire plans to submit for FDA accelerated approval in Q3 2025.
Aspire Biopharma (NASDAQ:ASBP) has announced positive top-line results from its clinical trial evaluating a new sublingual aspirin product for treating suspected acute myocardial infarction (heart attack). The randomized crossover bioavailability study demonstrated that the sublingual formulation achieved higher and faster plasma concentrations of acetylsalicylic acid compared to standard chewed aspirin tablets.
The trial involved six healthy subjects aged 40-65 years who received 162mg aspirin doses across three treatment periods. The sublingual delivery system offers several advantages, including rapid absorption, faster onset of action, and reduced GI irritation. This development is particularly significant as AMI affects nearly 3 million Americans annually, with 800,000 experiencing heart attacks and 300,000 resulting in deaths.
Aspire Biopharma Holdings (NASDAQ:ASBP), a company developing patent-pending drug and supplement delivery technology, has announced its participation in the upcoming Sidoti Virtual Investor Conference. Interim CEO Kraig Higginson will present on August 20, 2025, at 1:45 PM Eastern.
The company will also host one-on-one meetings with investors on August 20-21, 2025. Investors can access the virtual presentation through Sidoti's registration platform, and a replay will be available on Aspire's investor relations website.
Aspire Biopharma (NASDAQ:ASBP) has successfully launched its innovative pre-workout supplement BUZZ BOMB™ at FitCon and FitExpo, distributing over 30,000 sample packs to attendees. The product features a unique sublingual delivery technology with 50mg of caffeine in four flavors: Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha.
The product differentiates itself through rapid absorption (under 2 minutes vs. traditional 20-30 minutes), convenient single-use packets, and precise energy management. Notable fitness figures including UFC fighter Bobby Maximus and MMA champion Brandon Copeland have provided positive testimonials. The product is now available for purchase through the company's e-commerce website buzzbomb.buzz.
Aspire Biopharma Holdings (NASDAQ:ASBP) has launched its new e-commerce platform, buzzbomb.buzz, featuring its innovative product BUZZ BOMB™, a sublingual pre-workout supplement. The product delivers 50mg of caffeine rapidly through a unique under-the-tongue delivery system, available in four flavors: Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha.
The new direct-to-consumer platform offers exclusive promotions, including special pricing and free shipping for registered customers. The company is offering both sample packs of all four flavors and 30-pack configurations. To support the launch, Aspire plans to showcase the product at two major fitness conventions in early August.